<DOC>
	<DOCNO>NCT00864747</DOCNO>
	<brief_summary>The purpose study compare relative bioavailability Propranolol Hydrochloride Extended Release Capsules 160 mg ( Actavis ) INDERALÂ® LA 160 mg Capsules ( Wyeth Pharmaceuticals ) follow single oral dose ( 1 x 160 mg ) healthy adult volunteer non-fasting condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Propranolol HCl 160 mg Tablets Under Non-fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , single dose , two-way crossover study non-fasting condition Official Title : A Relative Bioavailability Study 160 mg Propranolol Hydrochloride Extended Release Capsules Under Non-Fasting Conditions Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Propranolol</mesh_term>
	<criteria>1 . Volunteers inform nature study agree read , review sign informed consent document prior Period I dose . 2 . Volunteers complete screen process within 28 day prior Period I dose . 3 . Volunteers healthy adult men woman 18 50 year age , inclusive , time dose . 4 . Volunteers body mass index ( BMI ) 1832 kg/m2 , inclusive , weigh least 110 lb . 5 . Volunteers healthy document medical history , physical examination ( include may limited evaluation cardiovascular , gastrointestinal , respiratory central nervous system ) , vital sign assessment , 12lead electrocardiogram ( ECG ) , clinical laboratory assessment , general observation . Any abnormalities/deviations normal range might consider clinically relevant study physician investigator evaluate individual case , document study file , agree upon study physician investigator prior enrol volunteer study continue enrollment . 6 . Volunteers negative urine drug screen . 7 . Female volunteer must negative pregnancy screen . 8 . Female volunteer practice acceptable method birth control judge investigator ( ) , condom spermicide , diaphragm spermicide , intrauterine device ( IUD ) , abstinence throughout duration study ; postmenopausal ( menses ) status least 1 year ; surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . 1 . Volunteers report receive investigational drug within 28 day prior Period I dose . 2 . Volunteers report presence history clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease determine clinical investigator ( ) . 3 . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . 4 . Volunteers demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . 5 . Volunteers report history allergic response ( ) propranolol relate drug . 6 . Volunteers report use systemic prescription medication 14 day prior Period I dose . 7 . Volunteers report use drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose . 8 . Volunteers report history clinically significant allergy include drug allergy . 9 . Volunteers report clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . 10 . Volunteers report history drug alcohol addiction abuse within past year . 11 . Volunteers demonstrate positive drug abuse screen study prior Period I dose administration . 12 . Volunteers currently use tobacco product . 13 . Volunteers report donate great 150 mL blood within 28 day prior Period I dose . All subject advise donate blood four week complete study . 14 . Volunteers report donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . 15 . Volunteers demonstrate positive pregnancy screen ( female ) . 16 . Volunteers currently pregnant breastfeed ( female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Propranolol</keyword>
	<keyword>Healthy subject</keyword>
</DOC>